Research Article
Solubility and Bioavailability Enhancement of Poorly Aqueous Soluble Atorvastatin: In Vitro, Ex Vivo, and In Vivo Studies
Table 2
Estimation of drug content for physical mixture, solid dispersion prepared by kneading, and solvent evaporation method.
| | Code | Ratios | Atorvastatin (mg) | Polymer (mg) | Drug content % |
| | PM 1 | 1 : 1 | 20 | 20 | 95.98 0.02 | | PM 2 | 1 : 3 | 20 | 60 | 98.74 0.13 | | PM 3 | 1 : 6 | 20 | 120 | 100.01 0.04 | | PM 4 | 1 : 9 | 20 | 180 | 102.21 0.1 | | KM 1 | 1 : 1 | 20 | 20 | 98.85 0.01 | | KM 2 | 1 : 3 | 20 | 60 | 98.41 0.17 | | KM 3 | 1 : 6 | 20 | 120 | 100.47 0.019 | | KM 4 | 1 : 9 | 20 | 180 | 101 0.124 | | SE 1 | 1 : 1 | 20 | 20 | 98.35 0.08 | | SE 2 | 1 : 3 | 20 | 60 | 99.12 0.4 | | SE 3 | 1 : 6 | 20 | 120 | 100.81 0.01 | | SE 4 | 1 : 9 | 20 | 180 | 100.32 0.06 |
|
|
; ATR: atorvastatin; PM: physical mixture; KM: kneading method; and SE: solvent evaporation method.
|
